Dulaglutide · source year
4 selected, source-linked Dulaglutide records carrying a 2019 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
3 represented types.
4 distinct public records.
Cited chronology
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 29910025 at 2026-07-30T20:57:06.150Z. PubMed recorded a metadata revision date of 2019-02-21 and an Entrez history date of 2018-06-19. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03824002 at 2026-07-30T20:57:18.709Z. Its registry update date was 2019-01-31, and PeptideScanner's reviewed identity mapping was dulaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 31 for the reviewed Dulaglutide label family with a published date of 2019-01-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 29852875 at 2026-07-30T20:58:13.922Z. PubMed recorded a metadata revision date of 2019-01-03 and an Entrez history date of 2018-06-02. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗